IMA
ImageneBio, Inc.
Price Chart
Latest Quote
$5.83
-0.17 (-2.83%)
Current Price
| Previous Close | $6.00 |
| Open | $5.83 |
| Day High | $5.83 |
| Day Low | $5.83 |
| Volume | 230 |
Stock Information
| Shares Outstanding | 11.28M |
| Total Debt | $2.42M |
| Cash Equivalents | $117.21M |
| Net Income | $-53.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $65.76M |
| EPS (TTM) | $-4.78 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-47.12M |
| Income | $-53.89M |
| Book/sh | $10.93 |
| Cash/sh | $10.39 |
| Employees | 17 |
Financial Ratios
| Quick Ratio | 17.67 |
| Current Ratio | 18.39 |
| Debt/Eq | 1.96 |
Returns & Margins
| ROA | -45.62% |
| ROE | -86.16% |
Ownership
| Insider Ownership | 14.96% |
| Institutional Ownership | 55.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.46 |
| P/B | 0.53 |
Analyst Data
| Recommendation | none |
| Target Price | $24.00 |
Technical Indicators
| SMA20 | $5.71 |
| SMA50 | $5.73 |
| SMA200 | $6.70 |
| RSI | 68.71 |
| ATR | 0.3115 |
| Shares Float | 5.80M |
| Short Float | 4.01% |
| Short Ratio | 10.15 |
| Rel Volume | 0.52 |
Performance History
| Week | +10.09% |
| Month | +7.91% |
| Quarter | +10.91% |
| 6 Months | -2.91% |
| YTD | -11.24% |
| Year | -62.69% |
| 3 Years | -92.86% |
| 5 Years | -96.36% |
| 10 Years | -98.44% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $6.00 | 8,200 |
| 2026-06-23 | $6.01 | 9,200 |
| 2026-06-22 | $5.99 | 8,200 |
| 2026-06-18 | $6.00 | 34,300 |
| 2026-06-17 | $5.69 | 7,400 |
| 2026-06-16 | $5.45 | 15,100 |
| 2026-06-15 | $5.54 | 22,000 |
| 2026-06-12 | $5.62 | 13,300 |
| 2026-06-11 | $5.71 | 11,200 |
| 2026-06-10 | $5.51 | 10,400 |
| 2026-06-09 | $5.55 | 7,200 |
| 2026-06-08 | $5.63 | 7,500 |
| 2026-06-05 | $5.65 | 7,400 |
| 2026-06-04 | $5.69 | 5,500 |
| 2026-06-03 | $5.45 | 6,400 |
| 2026-06-02 | $5.45 | 45,900 |
| 2026-06-01 | $5.47 | 46,800 |
| 2026-05-29 | $5.88 | 10,700 |
| 2026-05-28 | $5.93 | 15,300 |
| 2026-05-27 | $5.93 | 21,600 |
| 2026-05-26 | $5.82 | 22,100 |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
đ° Latest News
Image Resources NL (ASX:IMA) Is About To Turn The Corner
Simply Wall St. âĸ 2026-04-01T20:11:14Z
Imax announces $28M opening weekend for Amazon/MGM/s âProject Hail Maryâ
TipRanks âĸ 2026-03-24T12:35:12Z
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
Simply Wall St. âĸ 2025-12-31T11:39:25Z
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
Simply Wall St. âĸ 2025-11-15T13:27:30Z
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
Zacks âĸ 2025-08-05T13:55:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $800,000 | $3,500,000 | $7,962,000 |
| Operating Revenue | $800,000 | $3,500,000 | $7,962,000 |
| Expenses | |||
| Total Expenses | $49,251,000 | $40,500,000 | $29,887,000 |
| Other Income Expense | $717,000 | $71,000 | $-137,000 |
| Other Non Operating Income Expenses | $717,000 | $71,000 | $-137,000 |
| Net Non Operating Interest Income Expense | $2,035,000 | $374,000 | $1,194,000 |
| Total Other Finance Cost | $-2,035,000 | $-374,000 | $-1,194,000 |
| Operating Expense | $49,251,000 | $40,500,000 | $29,887,000 |
| General And Administrative Expense | $20,726,000 | $8,391,000 | $7,961,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Net Interest Income | $2,035,000 | $374,000 | $1,194,000 |
| Normalized Income | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Net Income From Continuing And Discontinued Operation | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Total Operating Income As Reported | $-48,451,000 | $-37,000,000 | $-21,925,000 |
| Net Income Common Stockholders | $-52,395,000 | $-48,384,000 | $-32,038,000 |
| Net Income | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Net Income Including Noncontrolling Interests | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Net Income Continuous Operations | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Pretax Income | $-45,699,000 | $-36,555,000 | $-20,868,000 |
| Operating Income | $-48,451,000 | $-37,000,000 | $-21,925,000 |
| Interest Income | - | $374,000 | $1,194,000 |
| Average Dilution Earnings | - | $-11,816,000 | $-10,890,000 |
| Interest Income Non Operating | - | $374,000 | $1,194,000 |
| Per Share | |||
| Diluted EPS | $-9.64 | $-4.33 | $-2.87 |
| Basic EPS | $-9.64 | $-4.33 | $-2.87 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-47,418,000 | $-35,474,000 | $-18,830,000 |
| Reconciled Depreciation | $1,033,000 | $1,526,000 | $3,095,000 |
| EBITDA (Bullshit earnings) | $-47,418,000 | $-35,474,000 | $-18,830,000 |
| EBIT | $-48,451,000 | $-37,000,000 | $-21,925,000 |
| Diluted Average Shares | $4,870,906 | $11,181,676 | $11,181,676 |
| Basic Average Shares | $4,870,906 | $11,181,676 | $11,181,676 |
| Diluted NI Availto Com Stockholders | $-52,395,000 | $-48,384,000 | $-32,038,000 |
| Otherunder Preferred Stock Dividend | $7,046,000 | $11,816,000 | $10,890,000 |
| Tax Provision | $-350,000 | $13,000 | $280,000 |
| Research And Development | $28,525,000 | $32,109,000 | $21,926,000 |
| Selling General And Administration | $20,726,000 | $8,391,000 | $7,961,000 |
| Other Gand A | $10,523,000 | $5,746,000 | $5,359,000 |
| Salaries And Wages | $10,203,000 | $2,645,000 | $2,602,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $133,139,000 | $-160,565,000 | $-126,108,000 |
| Total Assets | $152,976,000 | $15,922,000 | $31,245,000 |
| Total Non Current Assets | $12,688,000 | $3,454,000 | $5,346,000 |
| Non Current Prepaid Assets | $4,878,000 | $69,000 | $123,000 |
| Non Current Deferred Assets | $0 | $1,888,000 | $0 |
| Non Current Note Receivables | $7,020,000 | $0 | - |
| Investmentin Financial Assets | $0 | $942,000 | $942,000 |
| Current Assets | $140,288,000 | $12,468,000 | $25,899,000 |
| Prepaid Assets | $3,643,000 | $267,000 | $204,000 |
| Receivables | $1,296,000 | $83,000 | $223,000 |
| Other Receivables | $1,296,000 | $83,000 | $223,000 |
| Cash Cash Equivalents And Short Term Investments | $135,349,000 | $12,118,000 | $25,472,000 |
| Cash And Cash Equivalents | $94,532,000 | $12,118,000 | $15,321,000 |
| Debt | |||
| Total Debt | $2,975,000 | $8,048,000 | $983,000 |
| Long Term Debt And Capital Lease Obligation | $713,000 | $239,000 | $565,000 |
| Current Debt And Capital Lease Obligation | $2,262,000 | $7,809,000 | $418,000 |
| Current Debt | - | $7,500,000 | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $19,837,000 | $176,487,000 | $157,353,000 |
| Total Non Current Liabilities Net Minority Interest | $8,603,000 | $159,278,000 | $147,859,000 |
| Other Non Current Liabilities | $870,000 | - | - |
| Tradeand Other Payables Non Current | $0 | - | - |
| Current Liabilities | $11,234,000 | $17,209,000 | $9,494,000 |
| Current Deferred Liabilities | $0 | $650,000 | $71,000 |
| Payables And Accrued Expenses | $6,084,000 | $7,819,000 | $7,999,000 |
| Payables | $1,439,000 | $5,290,000 | $6,012,000 |
| Accounts Payable | $1,439,000 | $5,290,000 | $5,875,000 |
| Non Current Deferred Liabilities | - | $0 | $71,000 |
| Interest Payable | - | $1,294,000 | $0 |
| Total Tax Payable | - | $0 | $137,000 |
| Equity | |||
| Common Stock Equity | $133,139,000 | $-179,532,000 | $-145,075,000 |
| Total Equity Gross Minority Interest | $133,139,000 | $-160,565,000 | $-126,108,000 |
| Stockholders Equity | $133,139,000 | $-160,565,000 | $-126,108,000 |
| Gains Losses Not Affecting Retained Earnings | $87,000 | $-1,791,000 | $-1,753,000 |
| Retained Earnings | $-230,053,000 | $-179,900,000 | $-143,332,000 |
| Preferred Securities Outside Stock Equity | $0 | $159,039,000 | $147,223,000 |
| Preferred Stock Equity | - | $18,967,000 | $18,967,000 |
| Other | |||
| Ordinary Shares Number | $11,181,639 | $11,181,676 | $11,181,676 |
| Share Issued | $11,181,639 | $11,181,676 | $11,181,676 |
| Tangible Book Value | $133,139,000 | $-179,532,000 | $-145,075,000 |
| Invested Capital | $133,139,000 | $-172,032,000 | $-145,075,000 |
| Working Capital | $129,054,000 | $-4,741,000 | $16,405,000 |
| Capital Lease Obligations | $2,975,000 | $548,000 | $983,000 |
| Total Capitalization | $133,139,000 | $-160,565,000 | $-126,108,000 |
| Additional Paid In Capital | $363,094,000 | $2,158,000 | $0 |
| Capital Stock | $11,000 | $18,968,000 | $18,977,000 |
| Common Stock | $11,000 | $1,000 | $10,000 |
| Preferred Stock | $0 | $18,967,000 | $18,967,000 |
| Dueto Related Parties Non Current | $7,020,000 | - | - |
| Long Term Capital Lease Obligation | $713,000 | $239,000 | $565,000 |
| Current Deferred Revenue | $0 | $650,000 | $71,000 |
| Current Capital Lease Obligation | $2,262,000 | $309,000 | $418,000 |
| Line Of Credit | $0 | $7,500,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,888,000 | $931,000 | $1,006,000 |
| Current Accrued Expenses | $4,645,000 | $2,529,000 | $1,987,000 |
| Investments And Advances | $0 | $942,000 | $942,000 |
| Net PPE | $790,000 | $555,000 | $4,281,000 |
| Accumulated Depreciation | $0 | $-333,000 | $-3,152,000 |
| Gross PPE | $790,000 | $888,000 | $7,433,000 |
| Leases | $0 | $227,000 | $3,298,000 |
| Other Properties | $790,000 | $547,000 | $4,010,000 |
| Machinery Furniture Equipment | $0 | $114,000 | $125,000 |
| Properties | $0 | $0 | $0 |
| Other Short Term Investments | $40,817,000 | $0 | $10,151,000 |
| Non Current Deferred Revenue | - | $0 | $71,000 |
| Available For Sale Securities | - | $942,000 | $942,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-47,844,000 | $-21,319,000 | $-18,538,000 |
| Operating Activities | |||
| Operating Cash Flow | $-47,844,000 | $-21,319,000 | $-18,233,000 |
| Cash Flow From Continuing Operating Activities | $-47,844,000 | $-21,319,000 | $-18,233,000 |
| Operating Gains Losses | - | $1,274,000 | $1,000 |
| Investing Activities | |||
| Investing Cash Flow | $-5,814,000 | $11,123,000 | $-10,454,000 |
| Cash Flow From Continuing Investing Activities | $-5,814,000 | $11,123,000 | $-10,454,000 |
| Capital Expenditure | - | - | $-305,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $71,130,000 | $0 | - |
| Financing Cash Flow | $135,468,000 | $6,906,000 | $150,000 |
| Cash Flow From Continuing Financing Activities | $135,468,000 | $6,906,000 | $150,000 |
| Net Other Financing Charges | $49,293,000 | $-594,000 | - |
| Net Common Stock Issuance | $71,130,000 | $0 | - |
| Common Stock Issuance | $71,130,000 | $0 | - |
| Dividends Received Cfi | $-5,215,000 | $0 | - |
| Other | |||
| Issuance Of Debt | $15,000,000 | $7,500,000 | $0 |
| Income Tax Paid Supplemental Data | $23,000 | $221,000 | $118,000 |
| End Cash Position | $94,532,000 | $12,118,000 | $15,321,000 |
| Beginning Cash Position | $12,118,000 | $15,321,000 | $44,006,000 |
| Effect Of Exchange Rate Changes | $604,000 | $87,000 | $-148,000 |
| Changes In Cash | $81,810,000 | $-3,290,000 | $-28,537,000 |
| Proceeds From Stock Option Exercised | $45,000 | $0 | $150,000 |
| Net Issuance Payments Of Debt | $15,000,000 | $7,500,000 | $0 |
| Net Short Term Debt Issuance | $15,000,000 | $7,500,000 | $0 |
| Short Term Debt Issuance | $15,000,000 | $7,500,000 | $0 |
| Net Investment Purchase And Sale | $-599,000 | $10,151,000 | $-10,151,000 |
| Sale Of Investment | $9,799,000 | $10,151,000 | $10,000,000 |
| Purchase Of Investment | $-10,398,000 | $0 | $-20,151,000 |
| Net PPE Purchase And Sale | $0 | $972,000 | $-303,000 |
| Sale Of PPE | $0 | $972,000 | $2,000 |
| Change In Working Capital | $-19,188,000 | $-1,516,000 | $898,000 |
| Change In Other Working Capital | $-650,000 | $510,000 | $-139,000 |
| Change In Other Current Liabilities | $-1,459,000 | $-425,000 | $-649,000 |
| Change In Other Current Assets | $-1,205,000 | $54,000 | $0 |
| Change In Payables And Accrued Expense | $-11,917,000 | $-1,578,000 | $1,586,000 |
| Change In Accrued Expense | $-9,097,000 | $-1,055,000 | $-2,300,000 |
| Change In Payable | $-2,820,000 | $-523,000 | $3,886,000 |
| Change In Account Payable | $-2,820,000 | $-523,000 | $3,886,000 |
| Change In Prepaid Assets | $-3,957,000 | $-77,000 | $100,000 |
| Other Non Cash Items | $340,000 | $13,965,000 | $-942,000 |
| Stock Based Compensation | $15,391,000 | $0 | - |
| Amortization Of Securities | $-71,000 | $0 | - |
| Depreciation Amortization Depletion | $1,033,000 | $1,526,000 | $3,095,000 |
| Depreciation And Amortization | $1,033,000 | $1,526,000 | $3,095,000 |
| Depreciation | $1,033,000 | $1,526,000 | $3,095,000 |
| Gain Loss On Sale Of PPE | $0 | $1,274,000 | $1,000 |
| Net Income From Continuing Operations | $-45,349,000 | $-36,568,000 | $-21,148,000 |
| Purchase Of PPE | - | $0 | $-305,000 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $-137,000 |
Fetched: 2026-06-23